- A focus on a smaller number of higher-quality patent deals and a more patient approach to licensing are improving Acacia's (NASDAQ:ACTG +16.4%) top-line performance, the company suggested on its CC (transcript). While new revenue agreements fell to 15 from 43 a year ago, and revenue-generating programs to 16 from 28, revenue soared 117% to $50.1M.
- EPS was pressured by a 91% increase in inventor royalties to $10.7M, and a 76% increase in contingent legal fees to $7.1M. However, litigation/licensing expenses only rose 9% to $10.8M. MG&A spend rose 14% to $7.9M, and amortization costs 23% to $15.5M.
- Acacia has thus far had 10 scheduled trial dates in 2014, up from 3 for the whole of 2013. Over 20 additional trials are scheduled for the first few months of 2015.
-
Q2 results, PR